Prikaz osnovnih podataka o dokumentu
A Lower Level of Post-Vaccinal Antibody Titer against Influenza Virus A H1N1 May Protect Patients with Autoimmune Rheumatic Diseases from Respiratory Viral Infections
dc.contributor | Della-Torre, Emanuel | |
dc.creator | Milanović, Milomir S. | |
dc.creator | Kadijević, Djordje | |
dc.creator | Stojanović, Ljudmila | |
dc.creator | Milovanović, Branislav | |
dc.creator | Djoković, Aleksandra | |
dc.date.accessioned | 2022-01-17T11:32:14Z | |
dc.date.available | 2022-01-17T11:32:14Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 1010-660X | |
dc.identifier.uri | https://www.mdpi.com/1648-9144/58/1/76 | |
dc.identifier.uri | http://ipir.ipisr.org.rs/handle/123456789/721 | |
dc.description.abstract | Background and Objectives: The concentration of antibodies against virus influenza A H1N1 in the titer (≥1:32) positively correlates with resistance to flu in healthy persons. In elderly and immune-compromised patients, an influenza vaccine may be less immunogenic. Hypothesis: A lower post-vaccinal antibody titer (≥1:16) may be sero-protective against respiratory viral infections in patients with autoimmune rheumatic diseases. Materials and Methods: Fifty patients with autoimmune rheumatic diseases (Systemic Lupus Erythematosus—24; Rheumatoid Arthritis—15; and Sjögren’s Syndrome—11), who were at least 65 years old or whose relative disease duration (disease duration/age) was greater than 1/8, were examined. Thirty-four of them were vaccinated with a trivalent inactivated non-adjuvant influenza vaccine. The antibody concentration against influenza virus A H1N1 was measured using the standardized hemagglutination inhibition test and patients who got any respiratory viral infection were registered. To test the hypothesis, a correlative analysis was applied, followed by a binary logistic regression that included potential confounding variables, such as age, disease duration and therapy (personal/health-related conditions). Results: Vaccinated patients were significantly less affected by respiratory viral infections (21% vs. 75%). The lower titer considered (≥1:16) was significantly present more often among vaccinated patients (68% vs. 6%). The correlation between its presence/absence and that of respiratory viral infections was –0.34 (p < 0.05). The binary logistic regression evidenced the relevance of this correlation, confirming the hypothesis. Vaccination was associated with the 87.3% reduction in the likelihood of getting respiratory viral infections, whereas the lower antibody titer (≥1:16) was associated with the 77.6% reduction in the likelihood of getting respiratory viral infections. The vaccine was well tolerated by all patients and after vaccination no exacerbation of the underlying disease was observed. Conclusions: A lower antibody titer (≥1:16) against influenza virus A H1N1 could be protective against respiratory viral infections for certain autoimmune rheumatic diseases patients, which confirms the clinical effectiveness of influenza vaccination. | |
dc.language | en | |
dc.publisher | MDPI | |
dc.relation | info:eu-repo/grantAgreement/MESTD/inst-2020/200018/RS// | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | Medicina | |
dc.subject | autoimmune rheumatic diseases | |
dc.subject | clinical effectiveness of influenza vaccination | |
dc.subject | personal/health-related conditions | |
dc.subject | respiratory viral infections | |
dc.subject | sero-protective titer | |
dc.title | A Lower Level of Post-Vaccinal Antibody Titer against Influenza Virus A H1N1 May Protect Patients with Autoimmune Rheumatic Diseases from Respiratory Viral Infections | |
dc.type | article | en |
dc.type | article | |
dc.rights.license | BY | |
dc.citation.epage | 86 | |
dc.citation.issue | 1 | |
dc.citation.rank | M22 | |
dc.citation.spage | 76 | |
dc.citation.volume | 58 | |
dc.description.other | A part of this research study performed by D.M.K. was funded by the Ministry of Education, Science and Technological Development of the Republic of Serbia (Contract No. 451-03-9/2021-14/200018). Institutional Review Board Statement | |
dc.identifier.doi | 10.3390/medicina58010076 | |
dc.identifier.fulltext | http://ipir.ipisr.org.rs/bitstream/id/2189/bitstream_2189.pdf | |
dc.identifier.scopus | 2-s2.0-85122464307 | |
dc.identifier.wos | 000756976700001 | |
dc.type.version | publishedVersion |